These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9082335)

  • 1. [Diagnostic value of 123iodine-ibzm scintigraphy for staging of malignant melanomas].
    Henker C; Bida B; Markwardt J; Schlag P
    Nuklearmedizin; 1997 Jan; 36(1):1-6. PubMed ID: 9082335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl ] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging.
    Brenner W; Klomp HJ; Bohuslavizki KH; Szonn B; Kampen WU; Henze E
    Eur J Nucl Med; 1999 Dec; 26(12):1567-71. PubMed ID: 10638408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scintigraphic detection of melanoma metastases with a radiolabeled benzamide ([iodine-123]-(S)-IBZM).
    Maffioli L; Mascheroni L; Mongioj V; Gasparini M; Baldini MT; Seregni E; Castellani MR; Cascinelli N; Buraggi GL
    J Nucl Med; 1994 Nov; 35(11):1741-7. PubMed ID: 7965150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.
    Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW
    J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [123I]IBZM uptake in metastatic melanoma.
    Maffioli LS; Mascheroni L; Clemente C; Baldini M; Castellani MR
    J Nucl Biol Med (1991); 1993 Mar; 37(1):18-20. PubMed ID: 8329472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dopamine-D2 receptor scintigraphy with 123I-iodobenzofuran in malignant melanoma].
    Steinert H; Huch-Böni RA; Böni R; Westera G; Buck A
    Nuklearmedizin; 1995 Aug; 34(4):146-50. PubMed ID: 7675644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected detection of nodular melanoma of the skin on the scalp by I-123 IBZM brain SPECT.
    Booij J; Boot E; van Eeden S; van Amelsvoort T
    Clin Nucl Med; 2011 Feb; 36(2):148-9. PubMed ID: 21220985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sigma-receptor imaging by means of I123-IDAB scintigraphy: clinical application in melanoma and non-small cell lung cancer.
    Everaert H; Flamen P; Franken PR; Verhaeghe W; Bossuyt A
    Anticancer Res; 1997; 17(3B):1577-82. PubMed ID: 9179197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).
    Michelot JM; Moreau MF; Veyre AJ; Bonafous JF; Bacin FJ; Madelmont JC; Bussiere F; Souteyrand PA; Mauclaire LP; Chossat FM
    J Nucl Med; 1993 Aug; 34(8):1260-6. PubMed ID: 8326382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.
    Moins N; D'Incan M; Bonafous J; Bacin F; Labarre P; Moreau MF; Mestas D; Noirault E; Chossat F; Berthommier E; Papon J; Bayle M; Souteyrand P; Madelmont JC; Veyre A
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1478-84. PubMed ID: 12397467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma.
    Brandau W; Niehoff T; Pulawski P; Jonas M; Dutschka K; Sciuk J; Coenen HH; Schober O
    J Nucl Med; 1996 Nov; 37(11):1865-71. PubMed ID: 8917194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N; Rambaldi PF; Battista C; Ambrosio G; Cascini GL; Schillirò F; Mansi L
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma].
    Sillaire-Houtmann I; Bonafous J; Veyre A; Mestas D; D'Incan M; Moins N; Kemeny JL; Chossat F; Bacin F
    J Fr Ophtalmol; 2004 Jan; 27(1):34-9. PubMed ID: 14968075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A radiolabelled iodobenzamide for malignant melanoma staging.
    Rodot S; Darcourt J; Bussière F; Lacour JP; Migneco O; Thyss A; Michelot JM; Bonafous JF; Schneider M; Barety M
    Melanoma Res; 1994 Oct; 4(5):307-12. PubMed ID: 7858415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas.
    Bodei L; Hofland LJ; Ferone D; Mooy CM; Kros JM; Paridaens DA; Baarsma SG; Ferdeghini M; Van Hagen MP; Krenning EP; Kwekkeboom DJ
    Cancer Biother Radiopharm; 2003 Dec; 18(6):895-902. PubMed ID: 14969602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Radionuclide study of cutaneous melanomas with 99m Tc-HMPAO: visualization of metastases and recurrence].
    Collazo de la Maza AA; Borrón Molinos MC; Cordiés Justiz N; Pimentel González G; Sánchez Monzón I
    Rev Esp Med Nucl; 1999; 18(1):16-20. PubMed ID: 10074213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.